Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

@article{Chaft2011DiseaseFA,
  title={Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.},
  author={Jamie E Chaft and Geoffrey R. Oxnard and Camelia S. Sima and Mark G. Kris and Vincent A. Miller and Gregory J Riely},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 19},
  pages={6298-303}
}
PURPOSE Treatment of patients with oncogene-addicted cancers with tyrosine kinase inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We have observed that some patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib (RECIST progression after initial benefit) have accelerated progression of disease after discontinuation of TKI. To examine this observation and define the course of patients following TKI discontinuation, we… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 141 extracted citations

Disease flare after gefitinib discontinuation.

Respiratory investigation • 2015
View 11 Excerpts
Highly Influenced

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

Annals of oncology : official journal of the European Society for Medical Oncology • 2014
View 15 Excerpts
Highly Influenced

PKPD modeling of acquired resistance to anti-cancer drug treatment

Journal of Pharmacokinetics and Pharmacodynamics • 2017
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 27 references

First ling erlotinib vs. gemcitabline/carboplatin in activating EGFR mutationpositive advanced non-small cell lung cancer: efficacy and safety

C Wang, C Zhou, +3 authors Y Zhang
Clinical Cancer Research on April • 2011

Similar Papers

Loading similar papers…